Evolus, Inc. (EOLS) News
Filter EOLS News Items
EOLS News Results
|Loading, please wait...|
EOLS News Highlights
- EOLS's 30 day story count now stands at 10.
- Over the past 29 days, the trend for EOLS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- TGA, VRTX and BEAT are the most mentioned tickers in articles about EOLS.
Latest EOLS News From Around the Web
Below are the latest news stories about Evolus Inc that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.
No summary available.
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
NEWPORT BEACH, Calif., February 08, 2022--Evolus announces the acceptance of its submission to the Australian Therapeutics Good Administration for regulatory approval of Nuceiva®
NEWPORT BEACH, Calif., February 02, 2022--Evolus announces that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Evolus (EOLS – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals today and set a price target of $275.00. The company's shares closed last Wednesday at $226.58. According to TipRanks.
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
NEWPORT BEACH, Calif., January 26, 2022--Evolus announces its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.
Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.